August 2012
-
Leyden Laboratories has announced a €20 million venture debt financing deal with the European Investment Bank, with funds intended to support development of Leyden Labs’ antiviral nasal sprays, including PanFlu. The investment falls under the… Read more . . .
-
According to Cessatech, the Phase 2/3 Pediatric Study 0202 of the company’s CT001 sufentanil / ketamine nasal spray in children with severe pain met its primary endpoint, with more than half of patients reporting pain… Read more . . .
-
RDD Europe 2025, which took place in Estoril, Portugal May 6-9, welcomed approximately 490 delegates and 70 exhibitors from around the world to a meeting that focused on overcoming complex problems in order to advance inhaled… Read more . . .
-
According to Savara, the FDA has issued an RTF letter in response to the company’s BLA for Molbreevi molgramostim inhalation solution for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), citing insufficient CMC data. Savara completed… Read more . . .
-
At the end of March 2025, the FDA accepted Liquidia Corporations’s resubmitted NDA for Yutrepia dry powder treprostinil for inhalation for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung… Read more . . .
-
Nuance Pharma has announced that the Phase 3 ENHANCE-CHINA study of nebulized ensifentrine in patients with COPD has met its primary endpoint. The company obtained the rights to ensifentrine, a PDE3/PDE4 inhibitor, in China, Macau, Taiwan,… Read more . . .
-
According to Ritedose Pharmaceuticals, the FDA has approved an ANDA for the company’s generic albuterol sulfate inhalation solution, 0.5%. In April 2023, Ritedose announced that it had begun manufacturing 5 mg/ml albuterol sulfate inhalation solution… Read more . . .
-
Lupin has announced a new partnership with Honeywell and said that it will use Honeywell’s Solstice Air HFO-1234ze, a low global warming potential (LGWP) propellant, in Lupin metered dose inhalers. The announcement did not specify… Read more . . .
-
Rein Therapeutics (formerly Aileron Therapeutics) has announced the initiation of the Phase 2 RENEW trial of LTI-03, an inhaled dry powder caveolin-1 scaffolding domain peptide. The company had announced plans for the study in January 2025… Read more . . .
-
AstraZeneca announced the that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the company’s marketing application for a reformulated Trixeo (Breztri) Aerosphere budesonide / glycopyrronium / formoterol fumarate that uses Honeywell’s Solstice Air HFO-1234ze as… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.